Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

Gullu Gorgun, Gregory Whitehill, Jennifer L. Anderson, Teru Hideshima, Craig Maguire, Jacob Laubach, Noopur Raje, Nikhil C. Munshi, Paul G. Richardson, Kenneth C. Anderson

Research output: Contribution to journalArticle

191 Citations (Scopus)

Abstract

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population with the ability to suppress immune responses. MDSCs have been characterized in infections, inflammatory diseases, and solid tumors; however, their presence and role in the tumor-promoting, immune-suppressive microenvironment in hematologic malignancies remains unclear. We assessed the presence, frequency, and functional characteristics of MDSCs in patients with newly diagnosed, relapsed, and relapsed/refractory multiple myeloma (MM) compared with healthy donors. Additionally, we evaluated the immunomodulatory effects of lenalidomide and bortezomib on MDSCs in MM. CD11b +CD14-HLA-DR-/lowCD33+CD15 + MDSCs were significantly increased in both the peripheral blood and the bone marrow of patients with active MM compared with healthy donors. Furthermore, MDSCs induced MM growth while suppressing T-cell-mediated immune responses. Conversely, MM cells induced the development of MDSCs from healthy donor peripheral blood mononuclear cells, confirming a bidirectional interaction between MDSCs and MM cells and immune effector cells. Our results further suggest that MDSCs may be associated with the activity of disease in MM. Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)2975-2987
Number of pages13
JournalBlood
Volume121
Issue number15
DOIs
StatePublished - Apr 11 2013
Externally publishedYes

Fingerprint

Multiple Myeloma
Tumors
Blood
Neoplasms
T-cells
HLA-DR Antigens
Refractory materials
Bone
Cells
Tissue Donors
Myeloid-Derived Suppressor Cells
Hematologic Neoplasms
Myeloid Cells
Blood Cells
Bone Marrow
T-Lymphocytes
Growth
Infection

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Gorgun, G., Whitehill, G., Anderson, J. L., Hideshima, T., Maguire, C., Laubach, J., ... Anderson, K. C. (2013). Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood, 121(15), 2975-2987. https://doi.org/10.1182/blood-2012-08-448548

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. / Gorgun, Gullu; Whitehill, Gregory; Anderson, Jennifer L.; Hideshima, Teru; Maguire, Craig; Laubach, Jacob; Raje, Noopur; Munshi, Nikhil C.; Richardson, Paul G.; Anderson, Kenneth C.

In: Blood, Vol. 121, No. 15, 11.04.2013, p. 2975-2987.

Research output: Contribution to journalArticle

Gorgun, G, Whitehill, G, Anderson, JL, Hideshima, T, Maguire, C, Laubach, J, Raje, N, Munshi, NC, Richardson, PG & Anderson, KC 2013, 'Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans', Blood, vol. 121, no. 15, pp. 2975-2987. https://doi.org/10.1182/blood-2012-08-448548
Gorgun G, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J et al. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11;121(15):2975-2987. https://doi.org/10.1182/blood-2012-08-448548
Gorgun, Gullu ; Whitehill, Gregory ; Anderson, Jennifer L. ; Hideshima, Teru ; Maguire, Craig ; Laubach, Jacob ; Raje, Noopur ; Munshi, Nikhil C. ; Richardson, Paul G. ; Anderson, Kenneth C. / Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. In: Blood. 2013 ; Vol. 121, No. 15. pp. 2975-2987.
@article{768eb4fbe2ad4461b8bfb90aa6b4b5e8,
title = "Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans",
abstract = "Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population with the ability to suppress immune responses. MDSCs have been characterized in infections, inflammatory diseases, and solid tumors; however, their presence and role in the tumor-promoting, immune-suppressive microenvironment in hematologic malignancies remains unclear. We assessed the presence, frequency, and functional characteristics of MDSCs in patients with newly diagnosed, relapsed, and relapsed/refractory multiple myeloma (MM) compared with healthy donors. Additionally, we evaluated the immunomodulatory effects of lenalidomide and bortezomib on MDSCs in MM. CD11b +CD14-HLA-DR-/lowCD33+CD15 + MDSCs were significantly increased in both the peripheral blood and the bone marrow of patients with active MM compared with healthy donors. Furthermore, MDSCs induced MM growth while suppressing T-cell-mediated immune responses. Conversely, MM cells induced the development of MDSCs from healthy donor peripheral blood mononuclear cells, confirming a bidirectional interaction between MDSCs and MM cells and immune effector cells. Our results further suggest that MDSCs may be associated with the activity of disease in MM. Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy.",
author = "Gullu Gorgun and Gregory Whitehill and Anderson, {Jennifer L.} and Teru Hideshima and Craig Maguire and Jacob Laubach and Noopur Raje and Munshi, {Nikhil C.} and Richardson, {Paul G.} and Anderson, {Kenneth C.}",
year = "2013",
month = "4",
day = "11",
doi = "10.1182/blood-2012-08-448548",
language = "English (US)",
volume = "121",
pages = "2975--2987",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "15",

}

TY - JOUR

T1 - Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

AU - Gorgun, Gullu

AU - Whitehill, Gregory

AU - Anderson, Jennifer L.

AU - Hideshima, Teru

AU - Maguire, Craig

AU - Laubach, Jacob

AU - Raje, Noopur

AU - Munshi, Nikhil C.

AU - Richardson, Paul G.

AU - Anderson, Kenneth C.

PY - 2013/4/11

Y1 - 2013/4/11

N2 - Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population with the ability to suppress immune responses. MDSCs have been characterized in infections, inflammatory diseases, and solid tumors; however, their presence and role in the tumor-promoting, immune-suppressive microenvironment in hematologic malignancies remains unclear. We assessed the presence, frequency, and functional characteristics of MDSCs in patients with newly diagnosed, relapsed, and relapsed/refractory multiple myeloma (MM) compared with healthy donors. Additionally, we evaluated the immunomodulatory effects of lenalidomide and bortezomib on MDSCs in MM. CD11b +CD14-HLA-DR-/lowCD33+CD15 + MDSCs were significantly increased in both the peripheral blood and the bone marrow of patients with active MM compared with healthy donors. Furthermore, MDSCs induced MM growth while suppressing T-cell-mediated immune responses. Conversely, MM cells induced the development of MDSCs from healthy donor peripheral blood mononuclear cells, confirming a bidirectional interaction between MDSCs and MM cells and immune effector cells. Our results further suggest that MDSCs may be associated with the activity of disease in MM. Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy.

AB - Myeloid-derived suppressor cells (MDSCs) are a heterogeneous, immature myeloid cell population with the ability to suppress immune responses. MDSCs have been characterized in infections, inflammatory diseases, and solid tumors; however, their presence and role in the tumor-promoting, immune-suppressive microenvironment in hematologic malignancies remains unclear. We assessed the presence, frequency, and functional characteristics of MDSCs in patients with newly diagnosed, relapsed, and relapsed/refractory multiple myeloma (MM) compared with healthy donors. Additionally, we evaluated the immunomodulatory effects of lenalidomide and bortezomib on MDSCs in MM. CD11b +CD14-HLA-DR-/lowCD33+CD15 + MDSCs were significantly increased in both the peripheral blood and the bone marrow of patients with active MM compared with healthy donors. Furthermore, MDSCs induced MM growth while suppressing T-cell-mediated immune responses. Conversely, MM cells induced the development of MDSCs from healthy donor peripheral blood mononuclear cells, confirming a bidirectional interaction between MDSCs and MM cells and immune effector cells. Our results further suggest that MDSCs may be associated with the activity of disease in MM. Importantly, our studies suggest that inhibition of the tumor-promoting and immune-suppressive functions of MDSCs in MM may represent a promising novel immune-based therapeutic strategy.

UR - http://www.scopus.com/inward/record.url?scp=84879452593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879452593&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-08-448548

DO - 10.1182/blood-2012-08-448548

M3 - Article

C2 - 23321256

AN - SCOPUS:84879452593

VL - 121

SP - 2975

EP - 2987

JO - Blood

JF - Blood

SN - 0006-4971

IS - 15

ER -